188 related articles for article (PubMed ID: 22046967)
1. Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.
Geri G; Dadoun S; Bui T; Del Castillo Pinol N; Paternotte S; Dougados M; Gossec L
BMC Infect Dis; 2011 Nov; 11():304. PubMed ID: 22046967
[TBL] [Abstract][Full Text] [Related]
2. Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis.
Goeminne PC; Verschueren P; Scheers H; Dupont LJ
Clin Rheumatol; 2012 Feb; 31(2):367-73. PubMed ID: 21938452
[TBL] [Abstract][Full Text] [Related]
3. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
[TBL] [Abstract][Full Text] [Related]
5. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
Al-Mayouf SM; Alenazi A; AlJasser H
Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
[TBL] [Abstract][Full Text] [Related]
6. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.
Flint J; Panchal S; Hurrell A; van de Venne M; Gayed M; Schreiber K; Arthanari S; Cunningham J; Flanders L; Moore L; Crossley A; Purushotham N; Desai A; Piper M; Nisar M; Khamashta M; Williams D; Gordon C; Giles I;
Rheumatology (Oxford); 2016 Sep; 55(9):1693-7. PubMed ID: 26750124
[No Abstract] [Full Text] [Related]
7. Association between chest computed tomography findings and respiratory adverse events in rheumatoid arthritis patients undergoing long-term biological therapy.
Matsumoto T; Iwano S; Takahashi N; Asai S; Watanabe T; Asai N; Sobue Y; Ito S; Ishiguro N; Kojima T
Int J Rheum Dis; 2019 Apr; 22(4):626-635. PubMed ID: 30411520
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
[TBL] [Abstract][Full Text] [Related]
9. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
Espinoza F; Le Blay P; Combe B
J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
[TBL] [Abstract][Full Text] [Related]
10. A retrospective review of the adverse effects of biological therapy and reasons for its discontinuation in a resource-limited setting.
Rood JW; Du Toit R
S Afr Med J; 2020 Nov; 110(12):1231-1237. PubMed ID: 33403971
[TBL] [Abstract][Full Text] [Related]
11. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology.
Carrara G; Bortoluzzi A; Sakellariou G; Silvagni E; Zanetti A; Govoni M; Scirè CA
Clin Exp Rheumatol; 2019; 37(1):60-66. PubMed ID: 30148440
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
Pettipher C; Benitha R
Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
[TBL] [Abstract][Full Text] [Related]
13. How dangerous are norovirus infections in patients with rheumatic diseases treated with biologics and DMARDs? Follow-up on a local outbreak and comparison with a control cohort.
Fiehn C; Miehle N
Ann Rheum Dis; 2014 Apr; 73(4):786-7. PubMed ID: 24276367
[No Abstract] [Full Text] [Related]
14. [Biologics].
Kalden JR
Z Rheumatol; 2016 Aug; 75(6):604-10. PubMed ID: 27365024
[No Abstract] [Full Text] [Related]
15. [Biologics and cardiovascular risk].
Tarner IH; Müller-Ladner U; Hamm C
Z Rheumatol; 2010 Oct; 69(8):702-6, 708-11. PubMed ID: 20862482
[TBL] [Abstract][Full Text] [Related]
16. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
[TBL] [Abstract][Full Text] [Related]
17. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015.
Ge M; Man KK; Chui CS; Chan EW; Wong IC; Li X
Drug Saf; 2019 Sep; 42(9):1091-1102. PubMed ID: 31168709
[TBL] [Abstract][Full Text] [Related]
19. Infection risk and biologics: current update.
Wallis D
Curr Opin Rheumatol; 2014 Jul; 26(4):404-9. PubMed ID: 24827752
[TBL] [Abstract][Full Text] [Related]
20. Malignancy and the Risks of Biologic Therapies: Current Status.
Seror R; Mariette X
Rheum Dis Clin North Am; 2017 Feb; 43(1):43-64. PubMed ID: 27890173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
